HEARTCARE-B (06609) has announced that the company received a registration approval notice from the China Securities Regulatory Commission (CSRC) on May 14, 2026. The notice, with the approval number CSRC Permit [2026]1153, grants consent for the company's application to issue new domestic shares to specific investors. The key details of the approval are as follows: First, the CSRC has approved the company's application for a private placement of shares. Second, the issuance must be implemented strictly in accordance with the documents submitted to the CSRC. Third, this approval is valid for twelve months from the date of consent. Fourth, if any significant events occur from the approval date until the completion of the issuance, the company must promptly report to the CSRC and handle the matter according to relevant regulations.